In our series, KRAS, NRAS, BRAF, and PIK3CA mutations were observed in 47.5 % of the CRC cases examined, mostly confirming the mutation prevalence observed in our previous study (a mutation of at least one among the KRAS, BRAF, and PIK3CA genes was discovered in about 45 % of Sardinian CRC cases) [30]. This evidence concerns the gene NRAS and colorectal carcinoma.